MERGERS AND ACQUISITIONSAllergan shares rise on $2.5B deal for body-sculptor ZeltiqBy Sarah PringleFeb 13, 2017 11:11 AM EST
HEALTHCigna's cash pile won't go unused, if DOJ scuttles Anthem dealBy Sarah PringleFeb 9, 2017 11:41 AM EST
STOCKSAllergan followers optimistic ahead of Wednesday's fourth-quarter reportBy Sarah PringleFeb 7, 2017 12:22 PM EST
STOCKSBiotech premarket movers: PharmAthene, Earth Science Tech, PulmatrixBy Sarah PringleFeb 7, 2017 9:33 AM EST
STOCKSActivist-pressured Advisory Board launches strategic reviewBy Sarah PringleFeb 6, 2017 3:59 PM EST
STOCKSPfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'By Sarah PringleFeb 6, 2017 12:56 PM EST
STOCKSBiotech premarket movers: Cytokinetics, Artana Therapeutics, BluebirdBy Sarah PringleFeb 6, 2017 9:29 AM EST
MERGERS AND ACQUISITIONSHeth continues run at Reading InternationalBy Sarah PringleFeb 1, 2017 1:24 PM EST
STOCKSWhat Will You Hear on Pfizer's Fourth-Quarter Call Tuesday?By Sarah PringleJan 30, 2017 7:41 PM EST
MERGERS AND ACQUISITIONSDrugmakers plan huge deals in 2017, and banks will collect big feesBy Sarah PringleJan 29, 2017 6:43 PM EST
MERGERS AND ACQUISITIONSOdds of Surgery Partners' takeout growBy Sarah PringleJan 19, 2017 10:11 AM EST
STOCKSValeant's CEO tries to pitch Wall Street on the 'new Valeant' being very differentBy Sarah PringleJan 11, 2017 2:51 PM EST
STOCKS9 Allergan drugs may now cost as much as 9.5% more in 2017By Sarah PringleJan 7, 2017 3:03 PM EST
MERGERS AND ACQUISITIONSICU Medical Wins Big Price Cut to Buy Pfizer's Hospira UnitBy Sarah PringleJan 6, 2017 11:37 AM EST
STOCKSWhat pharma and health care services investors should watch for at JPMBy Sarah PringleJan 5, 2017 9:41 AM EST
STOCKSBiogen Scores FDA approval for first spinal muscular atrophy drugBy Sarah PringleDec 27, 2016 10:10 AM EST
MERGERS AND ACQUISITIONSInc Research Holdings seen as likely LabCorp. takeover targetBy Sarah PringleDec 12, 2016 11:19 AM EST
MERGERS AND ACQUISITIONSFred's hints that significant M&A is comingBy Sarah PringleDec 12, 2016 10:14 AM EST
STOCKSAttention shifts to Biogen's Alzheimer's drug in wake of Lilly resultsBy Sarah PringleDec 9, 2016 10:39 AM EST
CORPORATE GOVERNANCEQuestions mount at Teva as generics head quits without explanationBy Sarah PringleDec 6, 2016 10:05 AM EST
MERGERS AND ACQUISITIONSPerkinElmer medical imaging unit sale could be in the worksBy Sarah PringleDec 6, 2016 10:01 AM EST
MERGERS AND ACQUISITIONSAllergan Seeks to Reassure Antsy Investors Its Deals Will Pay OffBy Sarah PringleNov 30, 2016 11:24 AM EST
MERGERS AND ACQUISITIONSHere's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health UnitBy Sarah PringleNov 10, 2016 12:04 PM EST
STOCKSRepublican sweep poised to agitate ACA-vulnerable health care services stocksBy Sarah PringleNov 9, 2016 12:37 PM EST
MERGERS AND ACQUISITIONSMednax remains unlikely target as medical mergers gain steamBy Sarah PringleNov 1, 2016 5:33 PM EDT
STOCKSPfizer's Ian Read Sees No Size Limit to M&A, But Says Industry Is on PauseBy Sarah PringleNov 1, 2016 3:08 PM EDT
MERGERS AND ACQUISITIONSAnother mega health care deal: Blackstone buys back TeamHealthBy Sarah PringleOct 31, 2016 1:15 PM EDT
STOCKSThe internet of things is transforming healthcare, but there's one huge riskBy Sarah PringleOct 29, 2016 12:01 PM EDT
MERGERS AND ACQUISITIONSHca exits oklahoma as it continues to outpace peersBy Sarah PringleOct 27, 2016 4:33 PM EDT
MERGERS AND ACQUISITIONSPressure mounts at Community Health as liquidity concerns growBy Sarah PringleOct 27, 2016 12:44 PM EDT
MERGERS AND ACQUISITIONSBoston Scientific remains disciplined buyer in light of large-scale industry consolidationBy Sarah PringleOct 26, 2016 5:23 AM EDT
STOCKSAbbott CEO is unfazed by Muddy Waters' attack on St. JudeBy Sarah PringleOct 19, 2016 11:34 AM EDT
MERGERS AND ACQUISITIONSBlackstone bid for TeamHealth could hit $4 billionBy Sarah PringleOct 19, 2016 9:37 AM EDT
MERGERS AND ACQUISITIONSInvestor declares war on Community Health over Quorum SpinoffBy Sarah PringleOct 13, 2016 4:58 PM EDT
MERGERS AND ACQUISITIONSControversy over Allergan's 500% premium for Tobira looks overdoneBy Sarah PringleOct 12, 2016 4:15 PM EDT
MERGERS AND ACQUISITIONSCeo of russian cinema chain revealed as bidder for readingBy Sarah PringleOct 11, 2016 11:15 PM EDT
